Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
J Med Econ ; 20(8): 813-824, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28521540

ABSTRACT

BACKGROUND: Until recently, standard treatment of venous thromboembolism (VTE) concerned a combination of short-term low-molecular-weight heparin (LMWH) and long-term vitamin-K antagonist (VKA). Risk of bleeding and the requirement for regular anticoagulation monitoring are, however, limiting their use. Rivaroxaban is a novel oral anticoagulant associated with a significantly lower risk of major bleeds (hazard ratio = 0.54, 95% confidence interval = 0.37-0.79) compared to LMWH/VKA therapy, and does not require regular anticoagulation monitoring. AIMS: To evaluate the health economic consequences of treating acute VTE patients with rivaroxaban compared to treatment with LMWH/VKA, viewed from the Dutch societal perspective. METHODS: A life-time Markov model was populated with the findings of the EINSTEIN phase III clinical trial to analyze cost-effectiveness of rivaroxaban therapy in treatment and prevention of VTE from a Dutch societal perspective. Primary model outcomes were total and incremental quality-adjusted life years (QALYs), as well as life expectancy and costs. RESULTS: Over a patient's lifetime, rivaroxaban was shown to be dominant, with health gains of 0.047 QALYs and cost savings of €304 compared to LMWH/VKA therapy. Dominance was robustly present in all sensitivity analyses. Major drivers of the differences between the two treatment arms were related to anticoagulation monitoring (medical costs, travel costs, and loss of productivity) and the occurrence of major bleeds. CONCLUSION: Rivaroxaban treatment of patients with venous thromboembolism results in health gains and cost savings compared to LMWH/VKA therapy. This conclusion holds for the Dutch setting, both for the societal perspective, as well as the healthcare perspective.


Subject(s)
Anticoagulants/administration & dosage , Heparin, Low-Molecular-Weight/administration & dosage , Rivaroxaban/administration & dosage , Venous Thromboembolism/prevention & control , Anticoagulants/economics , Cost-Benefit Analysis , Female , Health Resources/economics , Health Resources/statistics & numerical data , Hemorrhage/chemically induced , Heparin, Low-Molecular-Weight/adverse effects , Heparin, Low-Molecular-Weight/economics , Humans , Male , Markov Chains , Middle Aged , Models, Econometric , Netherlands , Quality-Adjusted Life Years , Rivaroxaban/adverse effects , Rivaroxaban/economics , Secondary Prevention
2.
Drug Discov Today ; 17(7-8): 352-8, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22094244

ABSTRACT

In 2010, the European Regulation for Orphan Medicinal Products (OMPs) was in force for ten years. In this study we assessed possible determinants of applications for OMPs in the EU since 2000 that are associated with a successful marketing authorisation. Our analysis shows that clinical trial characteristics such as demonstrating convincing evidence of a beneficial effect on the primary endpoint, the selection of a clinically relevant endpoint, providing RCT data as pivotal study evidence and the submission of sound dose finding data are critical success factors. In addition, high medical need seems to counterweigh uncertainties about the scientific evidence in the benefit-risk assessment of OMPs.


Subject(s)
Drug Approval , Drug Industry , Marketing , Pharmaceutical Preparations , Europe , Humans , Risk Assessment
3.
Drug Discov Today ; 16(1-2): 73-80, 2011 Jan.
Article in English | MEDLINE | ID: mdl-21094692

ABSTRACT

The US Orphan Drug Act has fostered the development of drugs for patients with rare diseases by granting 'orphan designations', although several orphan drugs for which a marketing application has been submitted to the FDA have failed to obtain approval. This study identified the clinical trial design, the level of experience of the sponsor and the level of interaction with the FDA to be associated with non-approval. Sponsors, therefore, should engage in dialogue with the FDA and thoughtfully design pivotal clinical trials in accordance with FDA guidance documents.


Subject(s)
Clinical Trials as Topic/methods , Drug Approval/legislation & jurisprudence , Drug Approval/methods , Orphan Drug Production/legislation & jurisprudence , Animals , Humans , United States , United States Food and Drug Administration
4.
Drug Saf ; 33(2): 127-37, 2010 Feb 01.
Article in English | MEDLINE | ID: mdl-20082539

ABSTRACT

BACKGROUND: Drugs for rare diseases, so-called orphan drugs, are often intended for serious or chronically debilitating diseases. Safety information is more limited at the time of approval for orphan drugs as a result of various factors, such as the limited number of patients in clinical trials, quality of the clinical trials and special approval procedures. Several studies have been conducted on safety-related regulatory actions for drugs, but none of these have specifically focused on orphan drugs. OBJECTIVE: To determine the frequency and nature of safety-related regulatory actions for orphan drugs in the US and EU. METHODS: This cohort study examined publicly available data from the websites of US and EU regulatory authorities on orphan drugs approved in the US and/or the EU between January 2000 and December 2007. The main outcome measures were the nature, frequency and timing of safety-related regulatory actions, defined as (i) safety withdrawals; (ii) 'black-box' warnings; and (iii) written communications to healthcare professionals issued by the US FDA or the European Medicines Agency between January 2000 and June 2008. RESULTS: Ninety-five orphan drugs were approved during the study period (75 in the US, 44 in the EU, and 24 in both regions). Ten products (10.5%) received a safety-related regulatory action. No safety withdrawals, four black-box warnings and 12 written communications were identified. The probability of a first safety-related regulatory action for orphan drugs was 20.3% after 8 years of follow-up. Orphan drugs approved by accelerated approval (relative risk [RR] 3.32; 95% CI 1.06, 10.42), oncological products (RR 7.83; 95% CI 0.96, 63.82) and products for gastrointestinal and metabolism indications (RR 10.44; 95% CI 1.25, 87.27) may have a higher risk for a safety-related regulatory action. CONCLUSIONS: The probability of a first safety-related regulatory action for an orphan drug was slightly lower than that reported in the literature for biologicals in one study and new molecular entities in another study. However, detection of safety issues may be complicated by the limited experience with orphan drugs in practical use due to the low prevalences of the diseases they are used for. Doctors and pharmacists should therefore be vigilant with regard to the occurrence of a safety-related issue for orphan drugs.


Subject(s)
Adverse Drug Reaction Reporting Systems , Legislation, Drug , Orphan Drug Production , Cohort Studies , Drug Approval , Drug Labeling , European Union , Humans , United States
5.
Orphanet J Rare Dis ; 4: 27, 2009 Dec 14.
Article in English | MEDLINE | ID: mdl-20003427

ABSTRACT

BACKGROUND: Regulators and payers have to strike a balance between the needs of the patient and the optimal allocation of resources. Drugs indicated for rare diseases (orphan medicines) are a special group in this context because of their often high per unit costs. Our objective in this pilot study was to determine, for drugs used in an outpatient setting, how utilisation of centrally authorised drugs varies between countries across a selection of EU member states. METHODS: We randomly selected five orphan medicines and nine other drugs that were centrally authorised in the European Union between January 2000 and November 2006. We compared utilisation of these drugs in six European Union member states: Austria, Denmark, Finland, Portugal, The Netherlands, and Sweden. Utilisation data were expressed as Defined Daily Doses per 1000 persons per year. Variability in use across countries was determined by calculating the relative standard deviation for the utilisation rates of individual drugs across countries. RESULTS: No association between orphan medicine status and variability in use across countries was found (P = 0.52). Drugs with an orphan medicine status were more expensive and had a higher innovation score than drugs without an orphan medicine status. CONCLUSIONS: The results show that the variability in use of orphan medicines in the different health care systems of the European Union appears to be comparable to the other newly authorised drugs that were included in the analysis. This means that, although strong heterogeneity in access may exist, this heterogeneity is not specific for drugs with an orphan status.


Subject(s)
Drug Approval , Drug Utilization/statistics & numerical data , Orphan Drug Production , Austria , Denmark , European Union , Finland , Government Regulation , Health Services Accessibility/economics , Health Services Accessibility/legislation & jurisprudence , Humans , Legislation, Drug , Netherlands , Orphan Drug Production/economics , Orphan Drug Production/legislation & jurisprudence , Orphan Drug Production/statistics & numerical data , Pilot Projects , Portugal , Rare Diseases/drug therapy , Sweden
6.
Drug Discov Today ; 14(23-24): 1166-73, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19818412

ABSTRACT

More than 25 years of orphan drug regulations have yielded several new treatments for patients with rare diseases. Here, we show that successful translation of rare disease research into an orphan drug discovery and development programme is dependent on the disease class, its prevalence and the disease-specific scientific output. Our findings indicate that current orphan drug legislation alone is not sufficient to stimulate orphan drug development for diseases with a very low prevalence. Consequently, additional incentives should focus on stimulating the specific needs of rare disease research at disease class level.


Subject(s)
Drug Design , Drug Industry/economics , Orphan Drug Production , Rare Diseases/drug therapy , Research , Drug Approval , Humans , Legislation, Drug , Motivation
7.
Drug Discov Today ; 13(15-16): 670-6, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18583178

ABSTRACT

With the assignment of the 500th European Union orphan drug designation in 2007, the Regulation on Orphan Medicinal Products truly begins to show its potential for delivering new medicines to patients with rare diseases. Here, we analysed European orphan drug development at a national level and unveil a strong relationship between orphan drug development and pharmaceutical innovation performance in Europe. Moreover, we identify gaps in transition from science into orphan drug development as important bottlenecks that exist in several European countries. Our findings underline the importance of innovation-based policies to enhance the development of orphan drugs in Europe.


Subject(s)
Orphan Drug Production , Pharmaceutical Preparations , Drug Approval/economics , Europe , European Union , Government Regulation , Humans , Legislation, Drug , Orphan Drug Production/economics , Pharmaceutical Preparations/economics
8.
Eur J Clin Pharmacol ; 64(5): 545-52, 2008 May.
Article in English | MEDLINE | ID: mdl-18210097

ABSTRACT

OBJECTIVE: To encourage the development of drugs for rare diseases, orphan drug legislation has been introduced in the USA (1983) and in the EU (2000). Recent literature discusses factors that may influence the development of new orphan medicinal products in the EU. This study aims to identify predictors for successful marketing authorisation of potential orphan drugs in the EU. METHODS: A comparison between randomly selected authorised and a matched sample of not-yet-authorised orphan drug designations has been performed. Determinants in the study included characteristics of the indication, of the product and of the sponsor. Data were collected from the public domain only. RESULTS: Orphan drug approval was strongly associated with previous experience of the sponsor in obtaining approval for another orphan drug (OR = 17.3, 95% CI = 5.6-53.1). Furthermore, existing synthetic entities compared to biotechnology products tended to have a higher likelihood of reaching approval status (OR = 3.9, 95% CI = 0.9-16.6). CONCLUSION: This study showed that experience of a company in developing orphan drugs is an important predictor for subsequent authorisation of other orphan drugs. The same applies for existing (synthetic) molecules, for which much knowledge is available. Further research should be directed towards studying the quality of the clinical development program of those designated orphan medicinal products not reaching approval status.


Subject(s)
Drug Approval/statistics & numerical data , Drug Industry/statistics & numerical data , Orphan Drug Production , Rare Diseases/drug therapy , Drug Approval/legislation & jurisprudence , Drug Industry/legislation & jurisprudence , European Union , Humans , Prevalence , Rare Diseases/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...